Sanofi SA ((SNY)), Sanofi ((DE:SNW)), Sanofi ((SNYNF)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sanofi’s latest clinical study, titled ‘An Open Label Extension Study to Evaluate the Long-term Safety and Efficacy of Subcutaneous Lunsekimig in Adult Participants With Moderate-to-severe Asthma Who Participated in Study DRI16762,’ aims to assess the long-term safety and efficacy of Lunsekimig in adults with moderate-to-severe asthma. This study is significant as it provides insights into the prolonged effects of Lunsekimig, potentially offering a new therapeutic option for asthma management.
The intervention being tested is Lunsekimig, a drug administered via subcutaneous injection. It is designed to help manage moderate-to-severe asthma by providing sustained relief from symptoms.
The study is interventional, with a single-group assignment and no masking, focusing on treatment as its primary purpose. Participants from a prior study are eligible to continue in this extension study, receiving regular doses of Lunsekimig.
The study began on September 30, 2024, with an anticipated duration of up to 100 weeks, and the last update was submitted on August 4, 2025. These dates are crucial as they mark the progression and current status of the study, which is still recruiting participants.
This update could positively impact Sanofi’s stock performance by showcasing their commitment to advancing asthma treatments. Investor sentiment may be bolstered by the potential of Lunsekimig to address a significant market need, especially in the context of competing asthma therapies.
The study is ongoing, with further details available on the ClinicalTrials portal.